Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Avid Bioservices
Evaluate
October 12, 2016
Esmo event analyser – Tesaro tops the risers while Bristol-Myers is battered
March 17, 2016
Revisiting a predictor of failure in the post-Celator world
January 12, 2016
JP Morgan – Jumping in front of the cancer immunotherapy parade
April 22, 2015
Growth of anti-PD1 therapy threatens traditional second line chemo in NSCLC
June 28, 2013
Peregrine fails again and looks forward to phase III
January 08, 2013
Now you see it, now you don’t: Peregrine’s bavi might work after all
November 29, 2012
The curious solution to Curis’s pipeline conundrum
September 27, 2012
Peregrine crashes to earth after loan default
September 25, 2012
Peregrine's bavi dream turns into a nightmare
September 10, 2012
Peregrine’s bavi data: too good to be true?
August 17, 2012
Therapeutic Focus – Avastin provides glimmer in glioblastoma but progress still slow
Load More
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics